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ABSTRACT: Chronic liver inflammation (CLI) is a risk factor for development of hepatocellular carcinoma (HCC).
Galectin-1 (Gal1) is involved in the regulation of inflammation, angiogenesis, and tumorigenesis, exhibiting mul-
tiple anti-inflammatory and protumorigenic activities. We aimed to explore its regulatory role in CLI and HCC
progression using an established model of CLI-mediated HCC development, Abcb4 [multidrug-resistance 2
(Mdr2)]-knockout (KO)mice, which express high levels of Gal1 in the liver.We generated double-KO (dKO)Gal1-
KO/Mdr2-KOmice onC57BL/6 andFVB/Ngenetic backgrounds and comparedHCCdevelopment in the generated
strainswith theirparentalMdr2-KOstrains. LossofGal1 increased liver injury, inflammation, fibrosis, andductular
reaction in dKO mice of both strains starting from an early age. Aged dKO mutants displayed earlier hep-
atocarcinogenesis and increased tumor size compared with control Mdr2-KO mice. We found that osteopontin, a
well-knownmodulator ofHCCdevelopment, andoncogenicproteinsNtrk2 (TrkB) andS100A4wereoverexpressed
in dKO comparedwithMdr2-KO livers. Our results demonstrate that inMdr2-KOmice, a model of CLI-mediated
HCC, Gal1-mediated protection from hepatitis, liver fibrosis, and HCC initiation dominates over its known pro-
carcinogenic activitiesat later stagesofHCCdevelopment.These findings suggest that anti-Gal1 treatmentsmaynot
be applicable at all stages of CLI-mediated HCC.—Potikha, T., Pappo, O., Mizrahi, L., Olam, D., Maller, S. M.,
Rabinovich, G. A., Galun, E., Goldenberg, D. S. Lack of galectin-1 exacerbates chronic hepatitis, liver fibrosis, and
carcinogenesis in murine hepatocellular carcinoma model. FASEB J. 33, 7995–8007 (2019). www.fasebj.org
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About 25% of human cancers are associated with chronic
inflammation (1). To investigate the role of chronic in-
flammation in the development of hepatocellular carci-
noma (HCC), we use the Abcb4 [multidrug-resistance 2
(Mdr2)]-knockout (KO) mice as a model. These mice lack
the Mdr2 P-glycoprotein responsible for the phosphati-
dylcholine transport across the canalicular membrane and
develop chronic hepatitis and cholangitis at an early age,
inevitably followed by HCC at a later age (2). The gene
expression profiling that we performed on the Mdr2-KO
livers at the precancerous stages of liver disease revealed
aberrant expression of several immune and inflammatory
regulatory genes that have an important role in hep-
atocarcinogenesis, including up-regulation of Lgals1,
which encodes galectin-1 (Gal1) (3). Gal1 is widely
expressed in epithelial and immune cells and acts both
extracellularly and intracellularly, modulating innate
and adaptive immune responses and acting as a ho-
meostatic agent (4). It promotes apoptosis of activated
CD8 T cells, T helper (Th)1, and Th17 cells; suppresses
the secretion of proinflammatory IL-2 and IFN-g; and
favors the secretion of anti-inflammatory IL-10 andTGF-
b1 (5–7).Gal1 is a key effector of regulatory T cells (8) and
is required for the regulatory function of B cells (9). Gal1
overexpression in many types of tumors and/or sur-
rounding tissues promotes tumor progression by dif-
ferent mechanisms, including inhibition of antitumor
immune responses (5, 10, 11), by augmenting Ras acti-
vation (12) and by stimulating tumor angiogenesis
(13–15). Gal1 promotes HCC cell adhesion (16); it is
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overexpressed in human HCC (17, 18) and in Mdr2-KO
livers (at all tested ages and inmost tested tumors) (3, 19).
Gal1 also modulates cell survival and proliferation, act-
ing in different model systems as either a mitogen or an
inhibitor of cell proliferation (20). Thus, Gal1 may have a
dual effect on tumor development mediated by chronic
inflammation, acting either as an inhibitory mediator at
the early inflammatory stage of a disease or protumori-
genic at the later stages. Importantly,wehavepreviously
demonstrated that loss of Gal1 differentially affects re-
sponse of the FVB/NJ (FVB) and C57BL/6 (B6) inbred
mouse strains to acute liver inflammation (21). In order
to reveal the role of Gal1 in HCC development, we
generated double mutants Mdr2-KO/Lgals1-KO on the
FVB and B6 genetic backgrounds and compared HCC
development in these strains with their parental Mdr2-
KO strains for both sexes.
MATERIALS AND METHODS
Mice
Mice were housed at the specific pathogen-free unit of the Ani-
mal Facility at the Hebrew University Medical School, under a
12-h light/darkcycleandwereprovidedwith food (Teklad2918,
18% protein diet; Envigo, Somerset, NJ, USA) and water ad libi-
tum. All animal studies were approved by the Hebrew
University–Hadassah Medical School Ethics Review Board [the
Animal Care Unit holds National Institutes of Health (NIH;
Bethesda, MD, USA) approval OPRR-A01-5011 and the Ameri-
canAssociation for theAccreditation of LaboratoryAnimalCare
International accreditation 1285]. Wild-type B6 mice were
obtained from Envigo RMS Ltd. (Jerusalem, Israel); the Lgals1-
KO mutants of the B6 strain were kindly provided by Prof.
FrancoisePoirier (Institut JacquesMonod,Universités P6andP7,
Paris, France) and propagated in our facility. The Mdr2-KO/B6
and Gal1-KO/FVB mice were generated in our laboratory (21,
22). ThedKO/FVBanddKO/B6 strainswegeneratedbymating
Gal1-KOwithMdr2-KOmiceof eitherB6orFVBbackgrounds to
generate F1 double heterozygous mice. Then, F1 mice were
intermated to get the F2 progeny from which the appropriate
dKOgenotypeswere established.Toselect the requiredGal1-KO
andMdr2-KOgenotypes,DNAfrommouse tailswaspurifiedby
D-Tail Extraction Kit (Synthezza Bioscience, Jerusalem, Israel).
Genotyping was carried out by PCR analysis using primers
specific to Gal1, Mdr2, and Neo genes as previously described
(21). Amplicons were electrophoresed on 2% agarose gels.
Harvesting mouse liver tissue
At the indicated ages, mice were anesthetized with isoflurane,
blood was collected from the periorbital sinus, and anesthetized
micewere then euthanized by cervical dislocation. Allmicewere
operated at the same time interval between 12:00 AM and 3:00 PM
immediately after they were euthanized. The intact livers were
excised for tissueprocessingandweighed, andonepartwas fixed
in 4% neutral buffered formaldehyde for histology, while the
remaining liver tissue was snap-frozen for RNA and protein
analyses. The formalin-fixed livers were embedded in paraffin.
Blood analysis
Serumwas obtained by centrifugation of total blood at 3200 g for
10 min. Liver damage was assessed through the alanine amino-
transferase (ALT)andalkalinephosphatase (ALP)activities (U/L)
in the serum by an enzyme assay using Reflotron (Roche, Basel,
Switzerland).
Gene expression analysis
TotalRNAwas isolated from frozen (–80°C) liver tissueswith the
Trizol reagent (Thermo Fisher Scientific, Waltham,MA, USA) as
described by the manufacturer and used for either Nanostring
mRNA assay (NanoString Technologies, Seattle, WA, USA) or
quantitative RT-PCR. Reverse transcription of total RNA was
performed using the qScript cDNA Synthesis Kit (95047), and
quantitative RT-PCR was performed with Perfecta Sybr Green
Fast Mix Rox (95073; both Quanta BioSciences, Gaithersburg,
MD, USA). Reactions were run on a CFX384 Real-Time System
with C1000 Touch Thermal Cycle (Bio-Rad, Hercules, CA, USA)
and consisted of an initial denaturation for 20 s at 95°C followed
by 40 cycles of 1 s at 95°C and 20 s at 60°C. Following each run,
melting curves were generated to verify specific product forma-
tion. PCR primers specific for genes of interest were designed by
Primer-Blast (https://www.ncbi.nlm.nih.gov/tools/primer-blast) and
synthesized by Integrated DNA Technologies (Skokie, IL, USA).
Primers used in this study are shown in Supplemental Table S1.
Theprimer’s specificitywas ensuredusing2 typesof controls, the
firstwithout reverse transcriptase (1 for eachprimerpair) and the
second with no DNA template (1 for each primer pair). All
quantitative PCRs were run in triplicates. Data were analyzed
using CFX Manager software (Bio-Rad), and the expression of
each target gene was quantified relative to the expression of the
Hprt reference gene.
Cell culture and proliferation analysis
HepG2hepatoblastomacells (AmericanTypeCultureCollection,
Manassas, VA,USA) were maintained as amonolayer culture in
DMEM (Thermo Fisher Scientific) and supplemented with 10%
fetal bovine serumina5%CO2 incubatorat 37°C. Subculturingof
cells was carried out using 0.25% trypsin-EDTA (Thermo Fisher
Scientific). Cell proliferation was analyzed by using the xCEL-
Ligence System (Roche) that measures electrical impedance
across microelectrodes integrated into the bottom of tissue cul-
ture E-Plates.
Immunohistochemistry
Immunostaining was done on 4-mm–thick formalin-fixed
paraffin-embedded liver tissue sections by standard pro-
cedures. Haematoxylin and eosin–stained sections were used
to examine livermorphology.Masson’s trichrome stainingwas
performed for evaluating liver fibrosis. Pathology review was
performed in a blind fashion by an experienced pathologist
(O.P.) with the histologic scoring system for tumors.
The following antibodies to specific markers were used for
immunohistochemical staining: CD3 (1:200, MCA1477, CD34;
Sm1603; Acris, Herford, Germany), F4/80 (1:300; Serotec, Ox-
ford, United Kingdom), Ly6B.2 (1:300, MCA771GA; Serotec),
Ki67 (275R-14; Thermo Fisher Scientific), Ntrk2 (1:150, sc-377218;
SantaCruzBiotechnology,Dallas,TX,USA),panCK(1:400Z0622;
DakoCytomation, Glostrup, Denmark), S100A4 (1:200, ab40722;
Abcam, Cambridge,MA,USA), Opn gene (Spp1) (1:200, sc21742;
Santa Cruz Biotechnology), and vimentin (1:200, EPR3776;
Abcam). The following Horseradish Peroxidase-conjugated sec-
ondary antibodies were used: anti-rabbit (K4003), anti-mouse
(K4001; both EnVision, Glostrup, Denmark), and anti-rat (Histo-
fine, Nishirei, Japan). Color was developed using either 3-amino-
9-ethylcarbazole (AEC, 00-1111; Thermo Fisher Scientific) for 10
min (30min in the case of CD3) or 3,39-diaminobenzidene using a
Zymed Super Picture Kit (87-9663; Thermo Fisher Scientific) for 5
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min (b-catenin, F4/80). Counterstainwas performedwith filtered
Cat-Hematoxylin (Pharmatrade, Dubai, United Arab Emirates).
Negative controls were used by omitting the primary antibody.
Stainings were visualized with the Nikon Eclipse E600 micro-
scope equipped with the CellSens software imaging applica-
tions (Olympus, Tokyo, Japan). The number of F4/80+- and
Ki67+-expressing cells was counted on 10 random fields at
3200 magnification per slide, and a total of 4 or 5 mice per
group were used. For the morphometric assessment of Spp1,
Cd34, panCK, and Masson’s trichrome stained area, the in-
tegrated optical density was calculated using ImageJ Software
(NIH) in 10 random fields per section containing as similar a
size as possible of portal tract or hepatic vein at 3200 magni-
fication, and the results were averaged.
Statistical analysis
Statistical significancebetweengroupswasestimatedusingeither
the Fisher’s exact test (for tumor incidence) or the 2-tailed, un-
paired Student’s t test (in all other cases). Results are expressed as
means6 SEM; differences were considered significant at P, 0.05.
RESULTS
In order to identify possible molecular mechanisms un-
derlying enhanced tumor development in Gal1-deficient
Mdr2-KOmice, we compared the intensity of liver injury,
fibrosis, inflammation, and cell proliferation inMdr2-KO/
Gal1-KO (dKO) with Mdr2-KO mice at early (1–3 mo),
middle (6 and 9 mo), and terminal (12–18 mo) ages (Sup-
plemental Fig. S1). Mice were terminated at the age when
most animals develop tumors larger than 3 mm in di-
ameter. In both B6 and FVB strains, females develop tu-
mors earlier than males; thus, females were terminated
earlier. Notably, on the FVB genetic background, tumors
appeared earlier than on the B6 genetic background (21);
thus, FVB mice were terminated earlier than B6 mice of
both sexes. There was no difference in animal survival
between experimental groups (unpublished results).
Enhanced tumor development in the Mdr2-
KO/Gal1-KO compared with Mdr2-KO mice
Loss of Gal1 exacerbated HCC development in theMdr2-
KO mice on both genetic backgrounds (Fig. 1). The most
prominent effect caused by Gal1 loss was observed on the
B6 genetic background; dKO mice had increased tumor
incidence in both females (for tumors with diameter of at
least 3mm)andmales (for tumorswithdiameter of at least
8 mm; Fig. 1A). The percent of tumor-bearing mice at the
ageof 16mowas increased inB6dKOvs.Mdr2-KOmiceof
both sexes (Supplemental Fig. S3A). Tumor load was also
increased in the B6 dKOmice for small tumors in females
and for large tumors in males (Supplemental Fig. S2A–C).
Tumors of B6 dKOmice had higher differentiation grades
andhigher gradeof cell pleomorphism (Supplemental Fig.
S3C,D, respectively) and had a tendency toward a higher
mitosis rate (Supplemental Fig. S3B). On the FVB genetic
background, loss of Gal1 had no effect on tumor incidence
(Fig. 1B) but caused increased tumor load both in females
and males at the age of 1 yr (Supplemental Fig. S2D, E,
respectively).
Enhanced severity of the chronic
inflammatory disease in the Mdr2-KO/Gal1-KO
compared with Mdr2-KO mice at early age
At an early age, loss of Gal1 in Mdr2-KO mice of
both tested strains increased bile duct proliferation as
Figure 1. Loss of Gal1 enhances HCC development in Mdr2-KO/B6 mice. Incidence of tumors with diameters $0.3 cm.
A) Tumor incidence of the following experimental groups of B6 mice: 16-mo-old females (Mdr2-KO, n = 21 and dKO, n =
20), 16-mo-old males (Mdr2-KO, n = 32 and dKO, n = 24), and 18-mo-old males (Mdr2-KO, n = 26 and dKO, n = 31). B)
Tumor incidence of the following experimental groups of FVB mice: 12-mo-old females (Mdr2-KO, n = 15 and dKO, n =
12), 12-mo-old males (Mdr2-KO, n = 19 and dKO, n = 12), and 14-mo-old males (Mdr2-KO, n = 21 and dKO, n = 19). Only
nodules with diameters $0.3 cm were counted. F, females; M, males. Statistical significance was calculated using Fisher’s
exact test. *P = 0.05 for 1-tailed test and for tumors $0.3 cm, **P = 0.043 for 2-tailed test and for tumors $0.3 cm, ##P =
0.0076 for 2-tailed test for large tumors $0.8 cm.
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shown by enlarged ductular reactions (Fig. 2A, B) and
hepatocyte injury evidenced by higher levels of ALT ac-
tivity in the serum (Fig. 2C, D). Immunohistochemical
analysis of immune cell infiltration revealed increased re-
cruitment of monocytes and macrophages in the B6 dKO
compared with Mdr2-KO mice at 2 and 3 mo of age (Fig.
3A, B). Infiltration of T cells and neutrophils was low and
comparable between both tested groups (unpublished
results). Increased chronic liver inflammation (CLI) was
also reflected by augmented proliferation of hepatocytes
and nonparenchimal cells in the livers of double mutants
compared with B6 Mdr2-KO mice (Fig. 3C, D). To un-
derstand themolecularmechanismsunderlying increased
liver injury and cell proliferation of Gal1-deficient B6
Mdr2-KOmice, we compared transcript levels ofmultiple
known regulators of immune response and inflamma-
tion in the B6 dKO and Mdr2-KO mice by quantitative
RT-PCR and Nanostring technology. Genes that were
differently expressed between experimental groups are
represented in Fig. 3E, F, whereas genes that were
expressed at similar levels are listed in Supplemental
Tables S2 and S3.
Liver fibrosis was significantly more prominent in
B6 dKO vs.Mdr2-KO at 2 and 3mo of age (Fig. 4A). This
was accompanied by an increased expression of
fibrosis-associated genes Col1a,Mmp9, Sma1, and Spp1
in the liver of B6 dKO vs. Mdr2-KO mice at the age of
2 mo (Fig. 4B). Remarkably, the number of CD34-
positive cells in fibrotic septs and in the periphery of
bile ducts was significantly increased in the livers of
dKO vs. Mdr2-KO young mice of both FVB and B6
strains (Fig. 4C, D, respectively). A key role of bone
marrow–derived CD34-positive fibrocytes in the de-
velopment of hepatic fibrosis in Mdr2-KO mice has
been demonstrated (23). A significant increase of
ductular reaction in dKO vs. Mdr2-KO livers of both
mouse strains was detected at 1 and 3 mo of age (Fig.
5A, B). The increased Spp1 expression in dKO vs.
Mdr2-KO livers of both mouse strains was confirmed
at the protein level by immunostaining (Fig. 5C, D).
Remarkably, osteopontin (Opn) in the liver of all
tested Mdr2-KO mice was expressed mainly in
cholangiocytes.
We then tested the effect of Gal1 loss on the expression
of the Ntrk2 (TrkB) protein, one of the known Gal1 regu-
lators (24); this protein is frequently elevated in HCC and
associated with shorter patient survival (25). Ntrk2 was
significantly overexpressed in the liver of young dKO vs.
Figure 2. Increased bile duct proliferation, ductular reactions, and hepatocyte injury in the livers of dKO compared with Mdr2-
KO mice at young age. A, B) Hematoxylin and eosin staining of representative liver sections from Mdr2-KO and dKO mice from
FVB (A) and B6 (B) genetic background, 1 (upper panels) or 3 (bottom panels) mo of age. Ductal reactions are shown by arrows.
Representative images for animals (n = 6–8) of each particular group are shown. Original magnification,3200; scale bars, 20 mm.
C, D) Liver enzyme activities (units per liter) in the serum of young FVB (C) and B6 (D) males. For each time point, 6–9 mice
were used. The results are shown as means 6 SE. *P , 0.05, **P , 0.005 for dKO vs. Mdr2-KO.
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Mdr2-KOmice, both at themRNAand protein levels (Fig.
6A, B, respectively), and was localized mainly at the cy-
toplasm of hepatocytes, especially in the first layer of
pericentral hepatocytes (Fig. 6B).
Enhanced severity of the chronic
inflammatory disease in the Mdr2-KO/Gal1-KO
compared with Mdr2-KO mice at middle age
In order to follow the dynamics of chronic hepatitis and
cholangitis in dKO compared with Mdr2-KO mice,
we explored the extent of inflammation and fibrosis
markers in the livers of 6- and 9-mo-old mice of the B6
strain only. Histologically, livers of dKO mice were
characterized by a higher degree of inflammation
and biliary hyperplasia (Supplemental Fig. S4A). The
dKO mice had increased body and liver weights
(Supplemental Fig. S4B); however, the body–to–liver
weight index was similar to that of the Mdr2-KO mice
(unpublished results). At the age of 9mo, the dKOmice
showed significantly higher levels of ALT and ALP
activity in blood (Fig. 7A), indicating more severe in-
jury to both hepatocytes and cholangiocytes, compared
with the Mdr2-KO mice. At both middle ages tested,
livers of the dKOmice demonstrated higher infiltration
of neutrophils and macrophages (Fig. 7B, C, and Sup-
plemental Fig. S4C, D, respectively) and higher levels
of the S100A4andSpp1proteins (epithelial-mesenchymal
transition markers; Supplemental Fig. S5A, B, re-
spectively). At the age of 6 mo, dKO livers were char-
acterized by a higher degree of fibrosis (Fig. 7D) and
higher proliferation of both hepatocytes and non-
parenchymal cells (Fig. 7E). It should be mentioned that
in both tested middle ages (6 and 9 mo), expression of
Figure 3. Increased inflammation and proliferation of liver cells in dKO/B6 vs. Mdr2-KO/B6 livers. A) F4/80 immunostaining in
the Mdr2-KO/B6 (top panel) and dKO/B6 (bottom panel) livers. Red-brown signals distributed in the tissue represent F4/80+
monocytes and macrophages. Original magnification, 3100; scale bars, 50 mm. B) Quantification of F4/80+ cells as presented in
A in Mdr2-KO and dKO livers (mean of 5–6 males per each experimental group; 10 images were collected and analyzed per
mouse). C) Ki67 immunostaining in the livers of 2- and 3-mo-old Mdr2-KO/B6 and dKO/B6 mice. White triangles point to
hepatocytes and black triangles to nonparenchymal (NPC) cells. Original magnification, 3200; scale bars, 20 mm. D)
Quantification of Ki67-positive hepatocytes (upper graphs) and Ki67-positive nonparenchymal cells (bottom graphs) as
presented in C. The counting was performed in the liver zone 2 for hepatocytes and zone 1 (periportal region) for NPC in the
original magnification, 3400 field; n = 3–5 mice/genotype. Means 6 SD. *P , 0.05, **P , 0.01 in dKO vs. Mdr2-KO mice
(Student’s t test). E, F) Expression of genes associated with inflammation in the liver of 2-mo-old Mdr2-KO and dKO mice
assigned by either quantitative RT-PCR (E) or by Nanostring assay (F). There were 4–6 mice for each time point. Results are
presented as a means 6 SD. *P , 0.05, **P , 0.005 (Student’s t test).
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vimentin and Cd34 genes was similar in the liver of B6
dKO and Mdr2-KO mice (unpublished results).
Molecular mechanisms of the enhanced
hepatocarcinogenesis in the Mdr2-KO/Gal1-KO
compared with Mdr2-KO mice
In order to reveal the molecular and cellular mechanisms
associated with the enhanced tumor development in the
dKO vs. Mdr2-KO mice, we analyzed morphologic, bio-
chemical, and histologic parameters of the appropriate
male mice at the ages when they generate tumors (Fig. 8
and Supplemental Fig. S6). In the FVB strain, dKO and
Mdr2-KOmales had similar levels of theALTactivity at 12
and 14 mo of age and a similar level of the ALP activity at
12 mo of age, whereas at 14 mo, dKO males had signifi-
cantly lower ALP activity in blood (Supplemental Fig.
S6A, B). The FVB dKOmales at the age of 12 mo also had
higher infiltration of macrophages and increased expres-
sion of Opn in the liver (Fig. 8B, E, respectively). In the B6
strain, dKOmales had higher ALT activity in the blood at
the age of 16 and 18 mo, whereas ALP blood activity in
dKO andMdr2-KOmales was similar (Supplemental Fig.
S6C, D, respectively). Liver and body mass were slightly
increased in dKOmales at both ages tested, whereas liver
and body weight index was slightly increased in dKO
males at the age of 18 mo only (Supplemental Fig. S6E).
The B6 dKO mice had increased expression of proin-
flammatory mediators, including Ccl5, Ccr1, Cxcl2, Ltbr,
and Saa1, and increased livermacrophage infiltration (Fig.
8A, B, respectively). In addition, livers of the B6 dKOmice
were characterized by significantly increased fibrosis (Fig.
8C) and enhanced biliary hyperplasia (Fig. 8D), accom-
panied by up-regulation of the Krt19 gene (Fig. 8F) and
increased expression of the fibrosis-associated genes Spp1
(Fig. 8E, bottom panels), Cola1a, and Mmp9 (Fig. 8F).
Figure 4. Increased severity of fibrogenesis in dKO/B6 vs. Mdr2-KO/B6 livers at young age. A) Masson’s trichrome stain and
morphometric assessment of Masson’s trichrome stained areas in Mdr2-KO and dKO livers using ImageJ Software. Original
magnification, 3100; scale bars, 50 mm; n = 4–5 mice/genotype. The values are means 6 SEM. *P , 0.05, **P , 0.01 for dKO vs.
age-matched Mdr2-KO mice. B) Increased hepatic expression of the fibrogenesis- and billiary-related genes in dKO compared
with Mdr2-KO/B6 murine livers at the age of 2 mo (n = 3–5 mice/genotype). Means 6 SD. *P , 0.05, **P , 0.01 for dKO vs.
Mdr2-KO mice (Student’s t test). C, D) IHC of CD34 and its quantification by morphometric analysis in the Mdr2-KO and dKO
mouse livers from FVB (C) and B6 (D) genetic backgrounds. Multiple CD34+ cells were observed in fibrotic septa (stars) and
around bile ducts (arrows) in dKO vs. Mdr2-KO livers (red-brown color); n = 4–6 mice/genotype. Counting per 320 power field.
Original magnification: 3100; scale bars, 50 mM; inserts (D), 3600; scale bars, 10 mM.
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Remarkably, Opnwas expressed almost exclusively in the
nontumor liver; among 20 tumors analyzed by immuno-
histochemistry (IHC) (10 from B6 Mdr2-KO and 10 from
B6 dKOmice of both sexes), Opn expression was detected
in only 1 tumor (from B6 dKO male). Immunohisto-
chemical staining of Gal1 in the liver of aged B6Mdr2-KO
mice revealed no correlation (or anticorrelation) between
expressions of this lectin and Opn protein (Supplemental
Fig. S7). In the liver of 9-mo-old B6 Mdr2-KO mice, Gal1
protein was localized mainly in the cytoplasm of non-
hepatocyte cells (cholangiocyte, endothelial, and immune
cells) and rarely in the cytoplasmandnuclei of hepatocytes
(Supplemental Fig. S7A). In the nontumor liver of 18-mo-
old B6 Mdr2-KO mice, Gal1 protein was localized in the
cytoplasm of hepatocytes and nonhepatocyte cells, in-
cluding cholangiocyte, endothelial, and immune cells,
whereas in tumors, itwas localizedwithin the cytoplasmic
and membrane compartments of hepatocyte cells and
rarely in thenuclei of hepatocytes (SupplementalFig. S7B).
In order to reveal molecular mechanisms associated to
enhanced HCC development in B6 dKO mice, we have
compared expression of multiple genes in the liver of B6
dKO vs. Mdr2-KO young and old males by quantitative
RT-PCR (Supplemental Table S2) and Nanostring assay
(Supplemental Table S3). These genes include cytokines,
chemokines, and immune regulators, including known
regulators of the protumorigenic microenvironment and
markers of liver progenitor cells (Epcam, Prom1, Cd24a,
Trop2). All genes listed in Supplemental Tables S2 and S3
were not differentially expressed in dKO and Mdr2-KO
livers; their expression was similar irrespective of the ge-
notype or undetectable.
Spp1 knockdown impairs proliferation of
HepG2 cells in vitro
Human HCC cell lines tested, HuH7 and Hep3B, did not
express Spp1, whereas hepatoblastoma HepG2 cells did
(unpublished results). In order to examine the cell-
autonomous effect of Spp1 on liver tumor cell pro-
liferation, we knocked down its expression with specific
small interfering RNAs in HepG2 cells in vitro and fol-
lowed cell proliferation using the xcCELLigence tech-
nology (Roche). In parallel, the same experiment was
performed in 24-cell plates for testing gene expression at
38 h post-transfection. Spp1 knockdown resulted in a
Figure 5. Increased severity of cholangiopathy in dKO/B6 vs. Mdr2-KO/B6 livers at young age. A, B) PanCK immunostaining
and its quantification by morphometric analysis in the livers of dKO and Mdr2-KO mice from FVB (A) and B6 (B) genetic
backgrounds. PanCK expression is mainly confined to the biliary epithelial cells. C, D) IHC of Spp1 expression and its
quantification by morphometric analysis in the livers of dKO and Mdr2-KO mice from FVB (C) and B6 (D) genetic backgrounds.
The Spp1 gene was expressed mainly in the biliary epithelial cells (arrows with closed head). Original magnification, 3100; scale
bars, 50 mm.
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significant retardation of HepG2 cell proliferation dur-
ing 38–63 h starting from the cell plating (Supplemental
Fig. S8A). Gene expression analysis by quantitative
RT-PCR showed significant down-regulation of SPP1,
CCND1, and CCNG1, encoding cyclins D1 and G1, re-
spectively (Supplemental Fig. S8B).
Expression of alternatively spliced Spp1
variants in the murine liver
The Spp1 gene expresses several alternatively spliced
variants both in the murine and human tissues (Supple-
mental Fig. S9). In order to explore which Spp1 isoforms
function in the Mdr2-KO mice, we tested expression of
these isoforms in themouse liver at different stages of CLI
and in liver tumors. There is only 60–70% similarity be-
tween mouse and human Spp1 genes and proteins. We
detected the silent mutation CTG → CTA in the Leucine
codon (is underlined in the Supplemental Fig. S9C). Using
RT-PCR followed by sequencing of the PCR product, we
found that in the liver of B6 Mdr2-KOmice, only variants
Spp1 1–3 and 1–5 are expressed (Supplemental Fig. S10).
Remarkably, 1–3 is themajor Spp1 variant inmurine liver,
whose expression is at least 2 orders of magnitude higher
than that of the 1–5 variant (Supplemental Fig. S10). At the
age of 2 mo, expression of the Spp1-3 variant was signifi-
cantly higher in the B6 dKO vs. Mdr2-KO mice (Supple-
mental Fig. S10A), in agreement with IHC data (Fig. 5D).
At the age of 16 mo, expression of the Spp1-3 variant was
significantly higher in the nontumor liver tissue from B6
dKO vs. Mdr2-KO mice (Supplemental Fig. S10B). Ex-
pression of the Spp1-3 in tumors was significantly lower
than in nontumor liver tissue for bothMdr2-KO and dKO
B6mice (Supplemental Fig. S10B). Nevertheless, the Spp1
transcript expression was detectable in tumors in contrast
to Spp1 protein (for all but one of the analyzed tumors, as
mentioned above).
DISCUSSION
Gal1, a prototype member of the galectin family widely
expressed at sites of inflammation and tumor growth, can
influence tumor progression through multiple mecha-
nisms, including promotion of tumor inflammation, im-
munosuppression, angiogenesis, and metastasis (11, 26).
The marked up-regulation of Gal1 in the liver, its protu-
morigenic effects, and its broadanti-inflammatory activity
in a wide variety of pathologic settings prompted us to
investigate the role of this glycan-binding protein in CLI-
driven HCC development. Targeted inhibition of Lgals1
expression in a variety of tumors, including melanoma
cells, Hodgkin lymphoma, lung adenocarcinoma, pan-
creatic adenocarcinoma, breast adenocarcinoma and gli-
oblastoma, resulted in unleashed antitumor immunity,
leading to inhibition of tumor growth and metastasis
in syngeneic mice (26–30). From an immunologic stand-
point, this lectin impairs CD8, Th1, and Th17; deactivates
antigen-presenting cells; inhibits NK cells; and promotes
expansion of regulatory T cells (7, 29, 31–33). Recently,
Rutkowski and colleagues (34) found that this lectin
links tumor-promoting inflammation, immunosuppres-
sion, anddistant tumorgrowth.AlthoughGal1 is typically
up-regulated in cancer cells, in some tumor types, immune
and/or stromal cells appear tobe themainGal1 source (26,
34, 35). Moreover, Gal1 promotes tumor angiogenesis
(13–15) and augments Ras activation (12). Taking all these
data into consideration, the results of our study demon-
strating that Gal1 loss caused enhanced hepatocarcino-
genesis in the Mdr2-KO model are unexpected. The
exacerbating effect of Gal1 loss on CLI-mediated HCC
development in thismousemodelwasmore prominent in
the B6 strain, in agreement with our previous finding that
endogenous Gal1 efficiently protects murine liver from
acute inflammatory insult in the B6 but not in the FVB
genetic background (21). We suggest that enhanced HCC
development in the Mdr2-KO model could be explained
by the highly increased CLI in the absence of the Gal1
protein. Exacerbated CLI resulted in more severe liver
injury, fibrosis, and enhanced proliferation of hepatocytes
and nonparenchymal cells (Figs. 2 and 3). The accelerated
processes of liver tissue regeneration and remodeling
could generate more tumor-initiating cells (and at an ear-
lier stage) in dKO compared with Mdr2-KO mice. Thus,
the protumorigenic effect associated with Gal1 loss dom-
inated over the abovementioned antitumorigenic effects
Figure 6. Increased Ntrk2 expression in the liver of young dKO/
B6 vs. Mdr2-KO/B6 mice. A) Ntrk2 expression in the livers of 2-
mo-old B6 Mdr2-KO and dKO mice assessed by quantitative RT-
qPCR; n = 3–5 mice/genotype. Three transcript variants of
murine Ntrk2 were detected. Only transcript variant 2 (NM_
008745.3) could be distinguished from the other 2 transcripts
by quantitative RT-PCR. Left panel shows expression of the
transcript variant 2, whereas right panel shows expression of all
3 transcripts together (NM_001025074.2, NM_008745.3, NM_
001282961.1); 4–5 mice/assay were used. Means 6 SD. **P ,
0.005, ***P , 0.0005 in dKO vs. Mdr2-KO mice (Student’s t
test). B) IHC of the Ntrk2 protein in the livers of 2-mo-old B6
Mdr2-KO and dKO mice. Original magnification, 3200; scale
bars 20 mm.
8002 Vol. 33 July 2019 POTIKHA ET AL.The FASEB Journal x www.fasebj.org
linked to Gal1 blockade at later stages of hepatocarcino-
genesis. Importantly, the effect of Gal1 loss on hepatoc-
arcinogenesis was prominent during a relatively short
time period at the early cancerous stage (about 2-mo time
window at average), which was specific for each mouse
strain and sex (e.g., see Supplemental Fig. S2E, F). At older
ages, there was no statistically significant difference in
liver tumor incidence and load betweenGal1-positive and
Gal1-negative mice of both strains (unpublished results).
These results are consistent with the fact that Gal1 is just
one of multiple factors dictating the outcome of CLI-
mediated hepatocarcinogenesis. Likewise, loss of Gal1
resulted in only a 1-d retardation of liver regeneration (22).
Among possible molecular mechanisms that could
potentially contribute to the enhanced HCC development
in dKOmice, we foundup-regulation ofOpn (encoded by
the Spp1 gene) in the nontumor liver as one of the most
significant factors. Interestingly, Opn was overexpressed
in dKO compared with Mdr2-KO liver (mainly in chol-
angiocytes) at all tested ages (Figs. 3F, 4B, 5C, D, and 8E
and Supplemental Fig. S5B). Interestingly, there is still no
evidence linking Gal1 and Opn expression. In a previous
study exploring the role of Gal1 in liver regeneration (22),
we found no differences in Opn expression betweenGal1-
KO and wild-type mice at 2 and 3 d posthepatectomy
(unpublished results). Opn is a multifunctional protein,
which occurs in both secreted and intracellular forms and
interacts with the immune system and other cell types in
the injured liver. Depending on the type of injury and the
associated microenvironment, Opn may show opposing
roles in liver repair and carcinogenesis (36). In the chronic
liver injury accompanied by ductular reaction, Opn trig-
gers a crosstalk between epithelial and nonparenchymal
liver cells; it activates hepatic stellate cells, increases col-
lagen deposition, and stimulates proliferation of hepatic
progenitor cellswhile attenuatinghepatocyteproliferation
Figure 7. Increased liver inflammation and fibrosis in the middle-aged dKO/B6 vs. Mdr2-KO/B6 mice. A) ALT and ALP activity
in the serum of Mdr2-KO/B6 and dKO/B6 males 6 and 9 mo of age (5–8 mice for each time point and genotype). Means 6 SD.
*P , 0.05, **P , 0.01 in dKO vs. Mdr2-KO mice (Student’s t test). B, C) Quantification of Ly6G-positive (B) and F4/80-positive
(C) leukocytes in the liver of dKO vs. Mdr2-KO mice. The representative images are shown in Supplemental Fig. S4C and D,
respectively. D) Masson’s trichrome staining of the liver of 6-mo-old B6 dKO and Mdr2-KO males and its quantification by
morphometric analysis. Original magnification,3100; scale bars, 50 mm. E) Representative immunohistochemical staining of the
livers of 6-mo-old Mdr2-KO and dKO B6 males using Ki67-specific antibody. Hepatocytes are marked by white arrowheads and
nonparenchymal cells (NPCs) by black arrowheads. Original magnification, 3400; scale bars, 20 mM. F) Quantification of Ki67-
positive hepatocytes and Ki67-positive NPC. The counting was performed in liver zones 1 (periportal region) and 2 (middle
zone) for all tested liver sections; n = 3–5 mice/genotype. Means 6 SD. *P , 0.05, **P , 0.01 in dKO vs. Mdr2-KO mice
(Student’s t test).
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(37). Moreover, this protein also binds to LPSs, reducing
TNF availability (38). At late stages of hepatocarcino-
genesis, Opn expression is associated with accelerated
tumor progression and metastasis and lower patient sur-
vival (39–41). However, the role of Opn at early stages of
HCC development is still not clear, although it has been
proposed tomodulate the immunosuppressive activity of
myeloid-derived suppressor cells (42). Notably, 2 studies
exploring the role of Opn in HCC development using the
same model of Opn-deficient mice showed opposite re-
sults (43, 44). Noncancerous hepatocytes of HCC patients
did not express Opn (45). Furthermore, transgenic mice
expressing Opn in hepatocytes developed autoimmune
hepatitis at 24 wk of age (46). Among 240 HCCs, most of
which were of high grade and stage, Opn mRNA was
overexpressed in about 50%of tumors (39), whereas in the
cBioPortal data set of 360HCCs (47), it is overexpressed in
3.9% of HCC samples only (Supplemental Fig. S11A).
However, in both cases, HCC patients with tumors over-
expressing Opn had significantly lower survival. In this
regard, Gal1 mRNA was overexpressed in 5.8% of HCC
samples, but this effect did not impact patient survival
(Supplemental Fig. S11B). Expression of Opn by cancer
cells control their proliferation, leading to addiction as
demonstrated by our findings (Supplemental Fig. S8) and
the literature (40, 41). We suggest that in the Mdr2-KO
HCC model, Opn is induced in response to CLI, and this
effect is aggravated in the absence of Gal1. The effect of
OpnonHCCdevelopment inMdr2-KOmicemaybe stage
dependent (similar to that of Gal1), being tumor sup-
pressive at an early stage and protumorigenic at later
stages of CLI.
Figure 8. Gal1 loss enhances hepatic inflammation, fibrosis, and cholangiopathy in aged Mdr2-KO mice. A) quantitative RT-PCR
demonstrates increased expression of inflammation-related genes in hepatic nontumor tissues of 16-mo-old dKO/B6 mice (4–6
mice for each experimental group). Values for dKO mice were normalized to those of age-matched Mdr2-KO mice. Means 6 SD.
*P , 0.05, **P , 0.01 (Student’s t test). B) Immunostaining of F4/80+ monocytes and macrophages infiltrating nontumor
hepatic tissues of Mdr2-KO and dKO males from FVB and B6 genetic backgrounds. Original magnification, 3100; scale bars,
50 mM. C–E) Phenotypically, livers of dKO mice were much more stiff, hard, and often not smooth compared with the Mdr2-KO
livers of the both B6 and FVB backgrounds. Masson’s trichrome stain and fibrotic area quantification by morphometry in Mdr2-
KO and dKO nontumor liver tissues of 16-mo-old B6 mice using ImageJ software (C). IHC for panCK and its quantification
confirms high hepatic fibrogenesis in 16-mo-old dKO/B6 mice (D). Expression of Opn revealed by immunohistochemical
staining (E). Original magnification, 3100; scale bars, 50 mm. F) quantitative RT-PCR demonstrates increased expression of
hepatic genes related to fibrosis processing in nontumor liver tissues of 16-mo-old dKO/B6 vs. Mdr2-KO/B6 mice. Results are
presented as fold changes relative to Mdr2-KO mice. Means 6 SD. *P , 0.05, **P , 0.01 in dKO vs. Mdr2-KO mice; 4–6 mice for
each experimental group (Student’s t test).
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Similar to Gal1 andOpn, overexpression of the S100A4
protein in dKO liver could have different roles at different
stages of CLI in mutant mice. On one hand, S100A4 may
confer protection and show anti-inflammatory activity in
response to aberrations of lipidmetabolism (48), but on the
otherhand, itmay favor tumorprogressionandmetastasis
indifferent cancers (49), includingHCC (50). Furthermore,
overexpression of the Ntrk2 (TrkB) protein in hepatocytes
of the young dKO mice (Fig. 6) may contribute to the ex-
acerbation of hepatocarcinogenesis in the absence of Gal1.
Signaling through the TrkB receptor tyrosine kinase elicits
different processes essential for progression of epithelial
cancers, including epithelial-mesenchymal transition (51),
angiogenesis (25), and metastasis (52).
The results of our study demonstrate that in the Mdr2-
KO mouse model of CLI-mediated HCC, loss of Gal1 ex-
acerbates hepatocarcinogenesis, especially inmice bearing
the B6 genetic background. This effect is accompanied by
increasedCLI, fibrosis, and liver injuryat early animal age,
which in turn induces multiple protective mechanisms,
including overexpression of Opn and S100A4 proteins. At
the middle and late animal ages, these protective mecha-
nisms become less effective, and some of them, such as
Opn and S100A4, may trigger procarcinogenic activities,
resulting in increased tumorigenesis (Fig. 9). Hence, un-
like other cancer types, our findings suggest precaution in
the indication of anti-Gal1 treatment in CLI-mediated
HCC.
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